Sunday, September 13, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· January 22, 2026

4 Medical Supply Stocks Poised to Gain in a Prospering Industry

View original at finance.yahoo.com
4 Medical Supply Stocks Poised to Gain in a Prospering Industry The Zacks Medical - Dental Supplies industry in the Medical sector is likely to continue its upward momentum in 2026, backed by persistent innovation, an aging population with increasing healthcare needs and normalized orders following significant destocki…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Cardinal Health expects revenues from its Pharmaceutical segment to grow 15-17% year over year in fiscal 2026

    80% confidence
  • Align Technology views DSOs as a 'force multiplier' and expects them to remain a high-growth segment into 2026

    80% confidence
  • The Zacks Medical Dental Supplies industry is likely to continue its upward momentum in 2026

    80% confidence
  • Align Technology's restructuring actions are expected to lift operating margins by at least 100 basis points year over year in 2026

    80% confidence
  • The global medical supplies industry is expected to reach $163.5 billion by 2027, at a CAGR of 3.4% in the 2022-2027 period

    80% confidence
  • West Pharmaceutical aims for organic revenue growth of 7-9% over the long-term

    80% confidence
  • McKesson expects total revenues to grow 11-15% and operating profit to improve 12-16% in fiscal 2026

    80% confidence
  • A significant contract manufacturing agreement is set to expire in mid-2026, representing a $40 million headwind in the second half of 2026

    80% confidence
  • Cardinal Health expects adjusted EPS to be at least $10.00 for fiscal 2026

    80% confidence
  • Cardinal Health expects revenues from the Medical segment to grow 2-4% in fiscal 2026

    80% confidence
  • Cardinal Health expects revenues from the Other segment to grow 26-28% in fiscal 2026

    80% confidence
  • The rise of oral GLP-1 therapies increases the risk of future market share shifts from injectables, which could potentially pressure the top line

    80% confidence
  • The U.S. had 55.8 million people aged 65 and above in 2020

    80% confidence
  • Advanced robotics and automated storage and retrieval systems are transforming logistics, cutting human intervention by nearly 75% for some companies

    80% confidence
  • Although the company plans to mitigate tariff-related costs in 2026, they are likely to hurt margins this year

    80% confidence
  • DSOs have demonstrated an ability to grow at double-digit rates, even in mixed economic environments

    80% confidence
  • ClinCheck Live Plan can automate treatment plans in as little as 15 minutes

    80% confidence
  • McKesson expects fiscal 2026 earnings per share to be in the range of $38.35-$38.85

    80% confidence
  • Management indicated that the company intends to operate within its long-term model of 5-15% growth

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Capital Keeps Flowing as Enterprise Adoption and Government Contracts Validate the Bet
A late-August surge of nine-figure funding rounds (Socure, Stability AI, Generalist AI, Gatik, Regent Craft, Emerald AI, Owner) shows venture capital still pouring into AI infrastructure, identity/fintech, and autonomy, even as public-market sentiment stays jumpy — Palantir's stock fell 6% the same week it landed the Army's TITAN contract. UiPath's raised guidance and strong Q2 results, alongside efficiency breakthroughs like Multiverse Computing's model compression, point to real enterprise monetization catching up to the funding hype.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
JPMorgan Chase & Co.
Both facts record the same attribute (net_income) for JPMorgan Chase & Co. in the identical fiscal period (Q1 2026) and observation date (2026-03-31), but report values that differ by approximately 1 billion times: $16,494,000,000 vs $16.49. These cannot both be true simultaneously. The discrepancy suggests either a unit mismatch (e.g., one is total net income, the other earnings per share mislabeled as net_income), a decimal point error, or data entry corruption. For the same entity, attribute, and time period, only one value can be correct.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,981
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,981 facts checked against source5,280 source documents archived
Query this data → isubstrate.com